# OnCo record paper-zhu-clin-transl-sci (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-zhu-clin-transl-sci/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-zhu-clin-transl-sci" ;
  schema:name "Translational findings support regimen selection for first-in-human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer"@en ;
  schema:description "Paper cited by one treatment page and one target page, indexed on Europe PMC as PubMed record 39652449 and published in Clinical and translational science; the citing pages link this DOI, which is how the record was matched."@en ;
  schema:url <https://onco.cc/key-papers/paper-zhu-clin-transl-sci/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1111/cts.70082>, <https://pubmed.ncbi.nlm.nih.gov/39652449/>, <https://europepmc.org/article/MED/39652449> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1111/cts.70082> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Zhu M, Madia P, Crawford A, et al." ;
  onco:related <https://onco.cc/drugs/ubamatamab/>, <https://onco.cc/targets/muc16/> .